Loading...

Major Indexes

Discounted Cash Flow (DCF) Analysis Levered


PDS Biotechnology Corporation

PDS Biotechnology Corporation (PDSB)

$2.07
0.36 (+21.05%)

Free Cash Flow

Year
A/P
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue --------
Revenue (%)
Operating Cash Flow --------
Operating Cash Flow (%)
Capital Expenditure --------
Capital Expenditure (%)
Free Cash Flow --------

Weighted Average Cost Of Capital

Weighted Average Cost Of Capital

Share price $ 2.07
Diluted Shares Outstanding 4.87
Cost of Debt
Tax Rate 5.17
After-tax Cost of Debt -0.21
Risk-Free Rate
Market Risk Premium
Cost of Equity 2.46
Total Debt -
Total Equity 10.08
Total Capital 10.08
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue --------
Operating Cash Flow --------
Capital Expenditure --------
Free Cash Flow --------
WACC
PV LFCF --------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 2.46
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -
Equity Value -
Shares Outstanding 4.87
Equity Value Per Share -